Literature DB >> 21139486

Severe 2009 pandemic influenza A (H1N1) infection and increased mortality in patients with late and advanced HIV disease.

Christopher E Ormsby1, Daniela de la Rosa-Zamboni, Joel Vázquez-Pérez, Yuria Ablanedo-Terrazas, Ricardo Vega-Barrientos, María Gómez-Palacio, Akio Murakami-Ogasawara, Jorge A Ibarra-Ávalos, Dámaris Romero-Rodríguez, Santiago Avila-Ríos, Gustavo Reyes-Terán.   

Abstract

OBJECTIVE: To describe the clinical course of infection by 2009 (H1N1) influenza virus in different stages of HIV disease.
DESIGN: Prospective, observational study.
METHODS: During the pandemic period, HIV-infected patients presenting respiratory symptoms at a third level referral hospital in Mexico City were tested for 2009 influenza A (H1N1) viral RNA. Clinical files were prospectively analyzed.
RESULTS: Infection by H1N1 was confirmed in 30 (23.8%) of the total 126 HIV-infected patients studied. In the group of patients with 2009 H1N1 virus infection, 16 (53.3%) were hospitalized, 12 (40%) had active opportunistic infections and six (20%) died. In the group of 96 patients not infected with 2009 H1N1 virus, 54 (56.25%) were hospitalized with opportunistic infections and 12 (12.5%) died. For all hospitalized patients, being on HAART and having undetectable HIV viral loads at hospitalization was associated with higher survival (P = 0.019). Patients with 2009 H1N1 virus infection had a higher mortality rate, even after adjusting for HAART (P = 0.043). Coinfection by HIV and H1N1 2009 virus was more severe in patients with opportunistic infections, as shown by longer hospital stays (P = 0.0013), higher rates of hospitalization (P < 0.0001), use of mechanical ventilation (P = 0.0086) and death (P = 0.026). Delayed administration of oseltamivir in hospitalized patients was significantly associated with mortality (P = 0.0022).
CONCLUSION: Our data suggest that infection by 2009 H1N1 is more severe in HIV-infected patients with late and advanced HIV disease than in well controlled patients under HAART.

Entities:  

Mesh:

Year:  2011        PMID: 21139486     DOI: 10.1097/QAD.0b013e3283434844

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  18 in total

1.  Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses.

Authors:  Yanmei Hu; Jiantao Zhang; Rami Ghassan Musharrafieh; Chunlong Ma; Raymond Hau; Jun Wang
Journal:  Antiviral Res       Date:  2017-08-02       Impact factor: 5.970

2.  Randomized Controlled Trial to Compare Immunogenicity of Standard-Dose Intramuscular Versus Intradermal Trivalent Inactivated Influenza Vaccine in HIV-Infected Men Who Have Sex With Men in Bangkok, Thailand.

Authors:  Shikha Garg; Prasert Thongcharoen; Prabda Praphasiri; Anupong Chitwarakorn; Pornchai Sathirapanya; Stefan Fernandez; Kamonthip Rungrojcharoenkit; Wannee Chonwattana; Philip A Mock; Wichuda Sukwicha; Jacqueline M Katz; Marc-Alain Widdowson; Marcel E Curlin; Robert V Gibbons; Timothy H Holtz; Fatimah S Dawood; Sonja J Olsen
Journal:  Clin Infect Dis       Date:  2015-10-20       Impact factor: 9.079

3.  Cellular and humoral immune responses to pandemic influenza vaccine in healthy and in highly active antiretroviral therapy-treated HIV patients.

Authors:  Chiara Agrati; Cristiana Gioia; Concetta Castilletti; Daniele Lapa; Giulia Berno; Vincenzo Puro; Fabrizio Carletti; Eleonora Cimini; Carla Nisii; Flora Castellino; Federico Martini; Maria R Capobianchi
Journal:  AIDS Res Hum Retroviruses       Date:  2012-05-08       Impact factor: 2.205

4.  Influenza Viral Shedding in a Prospective Cohort of HIV-Infected and Uninfected Children and Adults in 2 Provinces of South Africa, 2012-2014.

Authors:  Claire von Mollendorf; Orienka Hellferscee; Ziyaad Valley-Omar; Florette K Treurnicht; Sibongile Walaza; Neil A Martinson; Limakatso Lebina; Katlego Mothlaoleng; Gethwana Mahlase; Ebrahim Variava; Adam L Cohen; Marietjie Venter; Cheryl Cohen; Stefano Tempia
Journal:  J Infect Dis       Date:  2018-09-08       Impact factor: 5.226

Review 5.  Influenza and HIV: lessons from the 2009 H1N1 influenza pandemic.

Authors:  Anandi N Sheth; Pragna Patel; Philip J Peters
Journal:  Curr HIV/AIDS Rep       Date:  2011-09       Impact factor: 5.071

Review 6.  Treating HIV-Positive/Non-AIDS Patients for Community-Acquired Pneumonia with ART.

Authors:  Catia Cillóniz; Antonella Ielpo; Antoni Torres
Journal:  Curr Infect Dis Rep       Date:  2018-09-10       Impact factor: 3.725

7.  Naturally-acquired influenza-specific CD4+ T-cell proliferative responses are impaired in HIV-infected African adults.

Authors:  Kondwani C Jambo; Enoch Sepako; Sarah J Glennie; David Mzinza; Neil A Williams; Stephen B Gordon; Robert S Heyderman
Journal:  PLoS One       Date:  2012-06-08       Impact factor: 3.240

8.  Seroincidence of Influenza Among HIV-infected and HIV-uninfected Men During the 2009 H1N1 Influenza Pandemic, Bangkok, Thailand.

Authors:  Shikha Garg; Sonja J Olsen; Stefan Fernandez; Charung Muangchana; Kamonthip Rungrojcharoenkit; Prabda Prapasiri; Jacqueline M Katz; Marcel E Curlin; Robert V Gibbons; Timothy H Holtz; Anupong Chitwarakorn; Fatimah S Dawood
Journal:  Open Forum Infect Dis       Date:  2014-10-10       Impact factor: 3.835

9.  Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine.

Authors:  Claire-Anne Siegrist; Christian van Delden; Michael Bel; Christophe Combescure; Cécile Delhumeau; Matthias Cavassini; Olivier Clerc; Sara Meier; Karine Hadaya; Paola M Soccal; Sabine Yerly; Laurent Kaiser; Bernard Hirschel; Alexandra Calmy
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

10.  HIV-1 and its gp120 inhibits the influenza A(H1N1)pdm09 life cycle in an IFITM3-dependent fashion.

Authors:  Milene Mesquita; Natalia Fintelman-Rodrigues; Carolina Q Sacramento; Juliana L Abrantes; Eduardo Costa; Jairo R Temerozo; Marilda M Siqueira; Dumith Chequer Bou-Habib; Thiago Moreno L Souza
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.